Lupin Aurangabad plant undergoes USFDA inspection
New Delhi: Drug major Lupin on Monday said the US health regulator has completed the prior approval inspection (PAI) of its Aurangabad manufacturing plant.
During the inspection, the US Food and Drug administration (USFDA) issued one 483 observation, Lupin said in a statement.
"The observation was procedural in nature and corrected during the inspection itself," it added.
As per USFDA, observations are made in Form 483 when investigators feel that conditions or practices in the facility are such that products may become adulterated or render injuries to health.
The FDA Form 483 notifies the company's management of objectionable conditions.
Last week, Unit 1 of Lupin's Pithampur facility had successfully undergone inspection on good manufacturing practice (GMP) as well as PAI by USFDA.
483 observationAurangabad plantgood manufacturing practicesinspectionLupinobservationprior approval inspectionUSFDA
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd